LMBRD2 Activators
The biochemical activation of LMBRD2 is facilitated by a suite of specific phosphodiesterase (PDE) inhibitors that modulate intracellular levels of cyclic nucleotides. In particular, the elevation of cAMP through the inhibition of PDE3, PDE4, and PDE5 leads to the activation of protein kinase A (PKA), a kinase that phosphorylates target proteins involved in various signaling cascades. LMBRD2, being a participant in these pathways, experiences enhanced activity as a result of this phosphorylation. As a consequence, the activation of adenylyl cyclase by compounds that directly increase cAMP levels further potentiates the functional capability of LMBRD2. This upregulation is not limited to cAMP-centric mechanisms, as the indirect impact of elevated cGMP levels, through the action of specific PDE inhibitors, also contributes to the activation of LMBRD2 by stimulating cGMP-dependent protein kinases which, in turn, can modify the activity of proteins within the same signaling networks as LMBRD2.
By inhibiting various isoforms of PDEs, the corresponding increase in cAMP and cGMP not only activates PKA and PKG pathways but also influences downstream signaling processes that LMBRD2 is an integral part of. The strategic elevation of these cyclic nucleotides ensures that LMBRD2 is functionally primed to respond to cellular cues, thereby optimizing its role in physiological processes. This fine-tuned regulation is achieved through the interconnected network of signaling pathways, where the presence of these nucleotides serves as a pivotal control point for the modulation of LMBRD2 activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Non-specific phosphodiesterase inhibitor that prevents cAMP degradation. This elevation in cAMP levels can enhance LMBRD2 activity by promoting signaling cascades that LMBRD2 is involved in. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Selective inhibitor of phosphodiesterase 5 (PDE5), which increases cAMP and cGMP levels. By elevating these cyclic nucleotides, LMBRD2 is indirectly activated through cAMP/cGMP-dependent pathways. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Phosphodiesterase 4 inhibitor that leads to increased cAMP levels. This boost in cAMP may enhance LMBRD2 activity through the activation of PKA signaling, which can modulate pathways LMBRD2 is associated with. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Phosphodiesterase 3 inhibitor that increases cAMP levels. Elevated cAMP can indirectly activate LMBRD2 by stimulating protein kinase A (PKA) and affecting pathways that converge on the regulation of LMBRD2 activity. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Selective phosphodiesterase 3 inhibitor that elevates cAMP levels. The increase in cAMP can potentiate LMBRD2 activity through PKA-dependent signaling pathways that LMBRD2 is involved in. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
PDE1 inhibitor which increases cAMP and cGMP levels. The elevation of these cyclic nucleotides enhances LMBRD2 activity by activating PKA and PKG pathways that modulate functions related to LMBRD2. | ||||||
Dipyridamole | 58-32-2 | sc-200717 sc-200717A | 1 g 5 g | $31.00 $102.00 | 1 | |
Phosphodiesterase inhibitor that increases cAMP and cGMP levels. By raising these nucleotides, the activity of LMBRD2 is indirectly enhanced through the subsequent activation of PKA and PKG signaling pathways. | ||||||
Theophylline | 58-55-9 | sc-202835 sc-202835A sc-202835B | 5 g 25 g 100 g | $20.00 $32.00 $85.00 | 6 | |
Non-selective phosphodiesterase inhibitor which leads to increased levels of cAMP. This rise in cAMP can indirectly activate LMBRD2 through the stimulation of cAMP-dependent protein kinase A (PKA) pathways. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Selective phosphodiesterase 3 inhibitor that results in increased cAMP levels. The heightened cAMP may indirectly activate LMBRD2 by modulating PKA-dependent pathways, thereby influencing the activity of LMBRD2. | ||||||